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- A 90 days oral toxicity study was conducted with propyl-propane-thiosulfonate 
- PTSO did not induce toxic effects at the highest dose assayed (55 mg/Kg/day) 
- NOAEL for PTSO was estimated to be ≥ 55 mg/Kg/day 
Highlights (for review)
Abstract 
Propyl-propane-thiosulfonate (PTSO) is one of the main organosulfur compounds 
present in Allium essentials oil. Different applications in the food sector have been 
proposed for PTSO, such as food and feed additive and as active packaging. However, 
the authorization of its use depends on its toxicity profile. Thus, as a part of its safety 
assessment, in this work a repeated dose 90-day oral toxicity study has been conducted 
for the first time in rats following the OECD guideline 408. PTSO was administered to 
groups of 10 male and 10 female rats at dose levels of 0, 14, 28, and 55 mg/Kg/day. No 
clinical signs or mortality and no changes in body weight, food consumption and feed 
conversion efficiency were detected through the study. Moreover, no treatment-related 
changes in hematological and biochemical parameters were observed, for either sex or 
dose groups. The histopathology study performed revealed no differences in organ 
weights, and no morphological and histopathological changes were observed. Based on 
these results, the no-observed-adverse-effect level (NOAEL) of PTSO was judged to be 
≥ 55 mg/Kg/day for both sexes. 
 







Essentials Oils (EO) extracts from plants have been the focus of numerous studies 
due to their potential in the pharmaceutical and food industries. Several works and 
patents have been developed specifically for the application of EO and their components 
into the food sector (Ribeiro-Santos et al., 2017; Llana-Ruiz- Cabello et al., 2015; 
Maisanaba et al., 2017). Globally, their relatively safe status, properties and acceptance 
by consumers which demand natural compounds to replace synthetic ones have piqued 
the interest of industries and consumers (Sacchetti et al., 2005; Benkeblia and Lanzotti, 
2007; Debiagi et al., 2014). Among those beneficial plants, Allium sp. is a genus well-
known for its antimicrobial, antiviral, antiprotozoal, antifungal or antioxidant properties 
(among others). These properties are mainly due to their content of organosulfur 
compounds (OSC), which are secondary phytochemical metabolites, biosynthesized for 
defensive purposes against biotic and abiotic stressors. They are mainly formed for the 
action of the enzyme alliin (stored in vacuoles) on cytoplasmic compounds like 
alk(en)yl cysteine sulfoxides (ACOs) once the vegetable tissue is hurt (Putnik et al., 
2019) (Fig. 1). Otherwise, these compounds are not available in intact cells as they are 
toxic for the plant (Ramirez et al., 2017).  
One of the main components of Allium essential oil is propyl-propane-thiosulfonate 
(PTSO), that corresponds to the molecular formula C6H14O2S2 (Fig. 1). This compound 
has been stabilized and characterized by DMC Research Center SLU ( Granada, Spain) 
to be used for different applications, taking advantage of its beneficial properties. Thus, 
this product has been reported to show mainly antioxidant and antimicrobial activities, 
being able to inhibit the growth of Gram (–) and Gram (+) bacteria as well as molds and 
yeast (Peinado et al., 2012, 2013; Llana-Ruiz-Cabello et al., 2015). Its antibacterial 
activity in vitro in humans has also been demonstrated (Sorlozano-Puerto et al., 2018).  
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Proallium AP®, a commercial Allium sp. extract with a 14.5% PTSO content, has 
been proposed as a biopreservative in active food packaging for human food 
commodities mainly due to its antioxidant and antimicrobial activity (Llana-Ruiz-
Cabello et al., 2018). The packaging material used in these systems can incorporate 
components intended to be released into the food from the package, allowing foods to 
arrive at the consumers with their original or enhanced organoleptic properties, with 
longer shelf-life and safety (Ribeiro-Santos et al., 2017). Previously, another study 
carried out by Seydim & Sarikus, (2006) tested the antimicrobial activity of garlic EO in 
combination with oregano EO in films made with whey protein isolate, and showed 
antimicrobial activity in a concentration of 4% (w/v). But the incorporation of garlic EO 
and their components in active food packaging can result in a higher human exposure 
and consequently, more research is needed to stablish the safety concentration. An 
additional proposed application for PTSO is as sensory additive in animal nutrition, 
improving the palatability of feed, and also as a zootechnical additive, being an 
alternative to the use of antibiotics (Peinado et al., 2012), contributing to reduce 
resistance generated by their excessive use in livestock. Since the ban in the European 
Union (EU)  of  the use of antibiotics as growth promoters, the search for new 
alternative products that ensure similar production levels and food security without 
generating unwanted effects, including human resistances, has been fostered, being 
additives of natural origin a good alternative. The regulation (EC) No 1831/2003 of the 
European Parliament and of the Council of 22 September 2003 sets the parameters of 
use of the additives used in animal nutrition. Recent studies have shown that some feed 
additives can help animals to maintain good physiological conditions and improve 
animal welfare. This has led to an amendment in the abovementioned regulation on 12th 
June 2019, establishing new functional groups of feed additives to improve 
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physiological condition of animals. In this regard, other properties demonstrating the 
potential use of PTSO in animal nutrition sector are the anti-methanogenic effect 
described during the fermentation process in rumen (Martínez-Fernández et al. 2013 ) 
and the immunomodulatory and anti-inflammatory properties (Vezza et al., 2019).  
However, the successful development of any application of this compound must be 
accompanied by an extensive toxicological evaluation, that guarantees its safety for the 
final consumers, both humans and livestock.   
In this regard, the toxicological profile of PTSO has been investigated by 
cytotoxicity assays in human cell lines (Llana-Ruiz-Cabello et al., 2015) as well as its 
genotoxicity and mutagenicity in vitro (Mellado-García et al., 2015) and genotoxicity in 
vivo (Mellado-Garcia et al., 2016b). Furthermore, its acute toxicity in vivo has been also 
evaluated (Llana-Ruiz-Cabello et al., 2015). Notwithstanding, safe doses of use have 
been not yet established for PTSO. Thus, a repeated dose 90-days oral toxicity study in 
rodents of PTSO would be necessary to clearly characterize its toxicity, being also a 
requirement in the authorization application processes of the European Food Safety 
Authority (EFSA, 2012; 2016a; 2016b; 2017).  
The aim of the present study is, therefore, to further explore the toxicity potential of 
PTSO and, for the first time, to conduct a subchronic dietary toxicity assay of PTSO in 
rats following internationally recognized test guidelines (Organisation for Economic 
Co-operation and Development, OECD 408, 2018). Considering these facts, in the 
present study several parameters have been evaluated, including body weight changes, 
food and water consumption, feed conversion efficiency, organ weight ratios  and 
biochemistry and hematology parameters. In addition the histopathology of various 
tissues has been also studied. The results from the complete assessment of this 
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subchronic study would allow to get an estimation of a non-observed-adverse-effect-
level (NOAEL) of exposure to establish safety conditions for human exposure to PTSO. 
 
2. Materials and Methods 
 
2.1. Test item and doses preparation 
PTSO was supplied by DMC RC SLU (Granada, Spain) with a 96% of purity. 
Commercial powder neutral gelatin from pork protein (Jesus Navarro S.A., Alicante, 
Spain) was employed as the vehicle for the test substance in all groups including the 
controls. 
For the 90-days study, the doses were prepared daily for each animal during the 
13 weeks, and on Fridays they were also prepared for the weekend. The dose was mixed 
in 3 mL of liquid gelatin. The volumes of PTSO (µL) to add to the gelatin depended on 
the dose selected for each group, and the gelatin could solidify at 4 ºC overnight. 
Homogeneity of the dietary dose formulations and their stability were confirmed to be 
at least 5 days. 
 
 
2.2. Animals conditions and husbandry services 
The rats were supplied by Charles River laboratories S.L. (Kings, NY, USA), 40 
males and 40 females of Sprague-Dawley strain. They were approximately 7 weeks old 
and were stabilized for an acclimatization period of 7 days during which they were 
examined by a veterinary surgeon. When the first week of dosage began the rats body 
weight mean was 320 g ± 11.3 for males and 227 ± 11.9 for females. 
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Animals were individually housed in cages type 3H with Souralit 29/12 plus 
(souralit S.L., Gerona, Spain) aspen wood bedding and food completely available 
without restriction using standard dry pellet diet for rodents Scientific (Panlab, S.L.U., 
Cornella de Llobregat, Barcelona, Spain). They were kept in a room with controlled 
conditions of hygiene behind a barrier system, a range of temperature of 21±2ºC, with a 
10-15 air changes per hour, and a relative humidity between 30-70% under 12 h 
light/dark cycle. Each cage contained an information card which contained study code 
(19-CAM-11-animal number), sex, dose, group, and individual animal identification. 
Community tap water (EMACSA, Cordoba Water company, Córdoba, Spain), filtered 
and autoclaved was available ad libitum.    
 
2.3. Study design 
The maximum tolerable dose (MTD) for PTSO in rats orally exposed to PTSO 
(gavage) was previously set at 55 mg/kg by Llana-Ruiz-Cabello et al., (2015) following 
the OECD 425 (2008) test guideline (oral toxicity study: Up and Down procedure), and 
it was used as a reference to establish the test doses. Accordingly, this dose was selected 
as the highest one to be tested, and also descending doses using a 2-fold interval factor 
according to the guideline OECD 408 (2018) recommendations: 14, 28, 55 mg/kg/day. 
Rats (10/sex/group) were orally administered the selected doses and the control group 
received only the vehicle (pork gelatine).  
 
This study was performed at the Central Service of Experimental Animals from 
the University of Cordoba (SAE, Cordoba, Spain) in which all animals received human 
care in accordance with the guidelines for the protection of animals used for the science 
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purposes (Directive, 2010/63 EU, Decision, 2012/707/UE, and RD 53/2013). All 
procedures have been approved by the Ethical Animal Experimentation Committee of 
the University of Córdoba and by the Junta de Andalucía (project nº 20/10/2015-348). 
 
2.4. Clinical observations 
 Each animal was observed twice daily for morbidity and mortality and once 
daily for clinical signs, such as changes in skin, fur, eyes or mucous membranes; 
secretions; changes in gait, posture, or handling response; abnormal, clonic, or tonic 
movements, and stereotypes or bizarre behavior. Ophthalmic examinations were 
performed on all animals before initiating the study and in the control and in the highest 
dose group at the end of treatment.  
 
2.5. Body weight, food and water consumption 
These three parameters were checked weekly in order to avoid stress. The mean 
body weight per group and sex were calculated weekly and prior to necropsy from 
individual animals’ data, as well as the food and water consumption. The total food 
consumed per cage was recorded and the weekly mean intake per rat was calculated. 
The feed conversion efficiency (FCE) ratio was determined according to Escobar et al., 
(2015) by the ratio of food intake (g)/ weight gained (g). 
 
2.6. Hematology and Biochemistry 
 Blood samples were extracted from the heart by an intracardiac injection under 
light isofluorane anesthesia at week 13. Then, the hematological parameters were 
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estimated on an automatic hematology analyzer Cell-Dyn 3700 (Abbot, GMI, MI, 
USA): red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean 
corpuscular volume (MCV), mean corpuscular hematoglobin (MCH), mean corpuscular 
hematoglobin concentration (MCHC), blood platelet count (PLT), red cell volume 
distribution (RDW), prothrombin time (PT), cefaline time (CT), white blood cell count 
(WBC), Neutrophils (NE), Lymphocites (LY), Monocytes (MO), Eosinophils (EO) and 
Basophils (BA). 
 An automatic chemistry analyzer Cobas 6000 (Roche Diagnostics, IN, USA) 
was used to determinate the following standard biochemistry parameters: glucose 
(GLUC), blood urea nitrogen (UREA), creatinine (CREAT), bile acids (BILI-T), total 
cholesterol (CHOL), triglycerides (TRIGL), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALKP), albumin (ALB), total protein 
(TOT PROT), sodium (Na+), potassium (K+) and Calcium (Ca 2+) ions. 
 
2.7. Necropsy and Organ weight 
 The animals were fasted for 18 h before the sacrifice and profoundly 
anaesthetized with isofluorane, then exsanguinated by intracardiac injection. All rats 
were given a complete pathology examination through the necropsy. The following 
organs were collected from animals at necropsy and weighed wet immediately after 
dissection: brain, liver, heart, spleen, kidneys, thymus, adrenal glands, uterus with 
cervix and ovaries (females) and testes and epididymis (males). In addition, tissue 
samples of the following organs were taken from the control and the highest dose (55 
mg/kg/day) group for histopathological examination under light microscopy: liver, 
kidney, spleen, heart, brain, pituitary, stomach, intestine, lung,  testicle/ovary and 
8 
 
skeletal muscle. Samples were fixed in 10% formalin for 24h at 4ºC, and then 
immediately dehydrated in graded series of ethanol, deep in xylol and embedded in 
paraffin wax using an automatic processor. Sections of 3-5 µm were mounted. After 
they had been deparaffinized, the sections were rehydrated, stained with hematoxylin 
and eosin, and mounted with Cristal/Mount (Paraplat, Oxford Labware, St. Louis, 
MO.). 
2.8. Statistical analysis 
All statistical analysis were carried out using Graph-Pad Instant software 
(GraphPadSoftware Inc., La Jolla, USA). Continuous variables, such as body weight, 
body weight gain, food and water consumption, hematology, clinical chemistry, and 
organ weight, were summarized using standard measures of central tendency and 
dispersion, mean and standard deviation (ST. DEV.), and were reported by sex and 
dosage. One-way analysis of variance (ANOVA) was carried out to test differences in 
continuous variables. Normality assumption was tested using Kolmogorov-Smirnov's 
test. If non-normality, comparison was performed with Kruskal Wallis test. In case of 
significant differences, multiple comparisons were performed using Tukey-
Kramer/Dunn's Multiple Comparisons Tests. Differences were considered significant 




3.1. Survival and clinical observations 
No unscheduled deaths occurred during the study. Light clinical signs were 
observed in some animals. Thus, sporadic alopecia was observed in rats 47, 59 and 62; 
small wounds in the ear of rat 52 and hematoma in the ear of rat 14 satisfactorily 
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recovered. These signs were not considered to be related to the test item, and were not 
biologically significant. Ophthalmologic examination revealed no compound-related 
lesions in the highest dose group of animals. No other clinical observations were noted. 
 
3.2. Body weight, body weight gain, food and water consumption, feed consumption 
efficiency 
Body weight increased along the study period following a usual pattern for this 
species. The test item did not induce any statistically significant alteration in this 
parameter (Fig. 2). Similarly, the body weight gain increased along the 13 weeks, with 
no differences between the control and the exposed groups in both sexes (Fig. 3). 
Food and water consumption per week did not show significant differences 
between control and treated groups, male and female, throughout the duration of the 
study, following the usual pattern (data not shown). The feed consumption efficiency 
also did not reveal any remarkable change for animals (Table 1). Thus, the test item did 
not have a negative impact on these parameters. 
 
3.3. Hematology and blood chemistry 
Hematology parameters evaluated in rats exposed to PTSO are provided in Table 
2. All variables considered remained unaltered in males. However, in females HCT (%) 
showed a significant increase (p<0.5) in groups 2 and 3 (14 and 28 mg/Kg/d, 
respectively) in comparison to group 4 (50 mg/Kg/d), and also the MCH (pg) 
experienced a significant decrease (p<0.5) in group 2 (14 mg/Kg/d) in comparison to 
group 3 (28 mg/Kg/d).  
10 
 
The differential White blood cells count did not show any change in any of the 
exposed groups and neither in males nor females (Table 3).  
Table 4 includes the clinical biochemistry values obtained for the parameters 
analyzed after the oral subchronic exposure of rats to PTSO. Most of them were not 
modified by the treatment. Only in males, a significant (p<0.01) decrease of Chol 
(mg/dL) values was observed in the highest dose group (55 mg/Kg/day), and also a 
significant increase (p<0.5) of TRIGL (mg/dL) in the lowest dose group (14 
mg/Kg/day), in comparison to the control group.  
In general, as the significant changes observed were minimal, sporadic, not 
present in all dose groups, neither in both sexes, they were considered incidental and not 
indicative of toxicity. 
 
3.4. Necropsy, organ weights and histopathology 
No gross pathologies were observed during the necropsy in any of the 
experimental animals. Also, organ weights were not altered by the treatment and only 
the mean heart weight of males of group 3 (28 mg/Kg/day) showed a slight but 
significant (p<0.5) decrease in comparison to the control group (Table 5). This was 
considered to be not related to the test item. Moreover, no significant changes were 
recorded in the organ weight/body weight ratio (Table 6) neither in the organ 
weight/brain weight ratio (Table 7).  
Regarding to the histopathological study performed, tissues of the rats, both 
male and female, exposed to the highest dose, did not revealed alterations in comparison 





The repeated dose 90-days oral toxicity study in rodents provides information on 
the possible health hazards likely to arise from repeated exposure over a prolonged 
period of time covering post-weaning maturation and growth into adulthood of the test 
animals. The study provides, among others, information on the major toxic effects, 
identification of target organs and also can provide an estimate of a non-observed-
adverse-effect level (NOAEL) of exposure which can be used in selecting dose levels 
for chronic studies and for establishing safety criteria for human exposure (OECD 408, 
2018). Moreover, an oral 90-days subchronic toxicity assay is usually included among 
the basic set of toxicity tests required in the evaluation of chemical substances with 
potential applications in the agri-food sector before their authorization. This is the case 
for example of food (EFSA, 2012a) and feed additives (EFSA, 2017), migrating food 
contact materials (EFSA, 2016a), or novel food (2016b). All this highlights the 
relevance of the study performed with PTSO, as this compound has shown beneficial 
properties with different potential applications previously described.  
The general absence of toxic effects observed after the treatment allows to estimate 
that the NOAEL for PTSO is ≥ 55 mg/Kg/day. Considering a safety factor of 100 
usually applied in food additives to derive human safety values from animal data 
(EFSA, 2012b), a dose of 0.55 mg/Kg/day could be suggested as a safe human exposure 
(~ 38,5 mg/day for a 70 kg b.w. person). However, this value is underestimated taking 
into account that a NOAEL could not be established from the assay performed and 
could be higher than 55 mg/Kg/day. 
The results obtained in the present study complete the information available in 
relation to the toxicity profile of PTSO. Thus, Llana-Ruiz-Cabello et al. (2015) 
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performed an acute oral toxicity test (Up-and-Down Procedure) following the OECD 
425 guideline (2008) and 55 mg/Kg b.w. was established as the maximum tolerated 
dose (MTD) in rats. However, in that case the exposure was by gavage whereas in the 
present study it was with the diet, a more realistic human exposure scenario. 
Mellado-García et al. (2015) performed a thorough in vitro genotoxicity assessment 
of PTSO including 4 different tests, among them the Ames test and the Micronucleous 
(MN) assay. This is the basic battery indicated by EFSA (2012) as they cover the three 
genetic endpoints required: gene mutations and both structural and numerical 
chromosome aberrations. They also performed the Mouse Lymphoma assay (MLA) and 
the Comet assay. They concluded that PTSO was not mutagenic in the Ames test, but it 
was mutagenic in the MLA assay after 24 h of treatment. The parent compound did not 
induce MN on mammalian cells; however, its metabolites  induced positive results. Due 
to inconclusive results, a follow-up of positive in vitro results by in vivo testing was 
performed. The genotoxicity of PTSO in rats following an oral administration of 5.5, 
17.4 and 55 mg/kg was evaluated by a combined in vivo comet assay and MN test 
(Mellado-Garcia et al., 2016a) and the results revealed no genotoxicity.  
All these results suggest a safety profile of PTSO for food applications at the doses 
assayed, but in a risk assessment frame it is well known that risk depends not only on 
the hazard but also in the human exposure level. In this regard, the level of PTSO to 
use, and therefore the potential exposure, will depend on the specific application 
considered. For instance, in the active packaging of lettuce, Llana-Ruiz-Cabello et al. 
(2015) estimated that in the worst-case scenario a human could ingest 6.87 mg PTSO, 
this means only a 18% of the dose calculated as safe in the present study. 
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The results obtained agree with those of Mellado et al. (2016b) who evaluated the 
safety of Proallium AP®, an Allium-based commercial product in a 90-days feeding 
study with rats. PTSO is actually the major organosulfur compound present in Proallium 
AP® (14.5%). Similarly, neither clinical signs nor any other changes on general, 
biochemical, hematological or histopathological parameters were detected, and the 
authors derived a NOAEL higher than 400 mg/Kg/day at the conditions assayed. Both 
studies show a good correlation as in the present study the test item had a 7-fold higher 
content of PTSO than Proallium® AP (100 versus 14.5%) and the NOAEL derived for 
Proallium was 7-fold higher. This suggests that PTSO has an important role on the 
toxicity of Allium extracts. Actually, a MTD of 55 mg/kg in rats for PTSO has been 
established as previously indicated. And higher doses tested according to the OECD 425 
guideline (2000 mg/kg and 175 mg/kg) resulted in the death of the animal and evident 
hepatotoxicity. On the contrary, a single dose of 55 mg/kg did not induce remarkable 
damage (Llana-Ruiz-Cabello et al, 2015). Mellado-García et al. (2016a) observed that in 
rats treated with 55 mg/kg (3 doses at 0, 24 and 45h and euthanized at 48h) an increase 
in the glycogen storage was noticeable in the liver and also a slight degenerative process 
in the chief cells of the stomach. 
In this regard, at the dose levels assayed, histopathological lesions were absent. This 
could be explained by the exposure way employed in this study, using gelatin as vehicle 
and with the feed. In the previous trials, oral gavage with a stomach tube after a fasting 
period was used following the recommendations of the corresponding OCDE 
guidelines. The bolus could have a more deleterious effect on the gastrointestinal 
system as there is a direct contact. 
Differences in toxicity between PTSO and Proallium AP® could be explained as the 
toxicity shown by components of an essential oil can be modulated by the other 
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constituents by synergistic/antagonistic phenomena (Escobar et al., 2015; Pavlidou et 
al., 2004). The interest of PTSO in comparison to Proallium® is based on its different 
chemical properties (higher hydrophilia) and in its higher efficiency on its antioxidant 
and antimicrobial properties.  
Other authors have shown the potential toxicity of aqueous extracts of different 
medicinal plants, including Allium sativum, in Wistar rats. Thus, Sulaiman et al. (2014) 
administered orally to the animals 10 mg/kg of A. sativum extract for 30 days and 
observed alteration in the activities of marker enzymes: AST increased in liver, kidney 
and heart, ALT in serum and liver, and ALP activity was reduced in serum, heart, 
kidney and liver. They concluded that caution was required in using unrefined extracts 
of these herbs in traditional settings. 
There are scarce in vivo toxicity data regarding other OSC. Thus, Guyonnet et al. 
(2000) demonstrated the effects of some of them (DAS, DADS, dipropylsulfiide (DPS) 
and dipropyl disulfide (DPDS)) on the activation of several mutagens in male Wistar 
rats exposed to 1 mmol/kg by gavage for 4 days. They explained the results based on 
the induction of cytochrome (CYP) and phase II enzymes activities. This effect, the 
alteration of CYP activity, was pointed out by other authors as well (Davenport and 
Wargovich, 2005). Moreover, they observed hepatotoxicity induced by DAS (bile duct 
obstruction, hyperproliferation and focal points of necrosis) in rats gavaged daily with 
200 mg/kg for 1, 4, or 8 weeks. On the contrary, 8 weeks of exposure to lower doses (50 
and 100 mg/kg) did not induced liver histophatological damage. This suggest that liver 
could be the target organ of OSC as both, DAS (Davenport and Wargovich, 2005) and 
PTSO (Llana-Ruiz-Cabello et al, 2015), have shown liver toxicity when a threshold 
dose is exceeded. Also, Wu et al. (2001) exposed rats orally to garlic oil (GO, 200 
mg/Kg) and 3 allyl compounds, DAS (20 and 80 mg/kg), DADS (80 mg/kg), and diallyl 
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trisulfide (DATS, 70 mg/kg) 3 times a week for 6 weeks and examined the antioxidation 
system in rat livers and red blood cells. They found that GO, DADS and DATS 
significantly induced the glutathione content (GSH) in blood cells but neither GO nor 
any of its OSC affected the GSH-related antioxidant enzymes. Hepatic GSH was not 
influenced by garlic components. But DADS and DATS significantly increased the 
activity of GSH-reductase and GSH-transferase and decreased GSH peroxidase. In the 
present study the hematological parameters were not influenced by the PTSO exposure 
and scarce scientific data dealing with PSTO are available to compare. 
 
5. Conclusions 
In conclusion, the results obtained confirm the already reported safety profile of 
PTSO for some food applications at the conditions considered. Thus, PTSO did not 
promote toxic effects as seen from body weight changes, food and water consumption, 
feed conversion efficiency, biochemical and blood parameters as well as organ toxicity 
and histological examinations of main organs that could eventually be affected by its 
subchronic administration (90 days). NOAEL was estimated to be ≥ 55 mg/Kg/day. 
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Fig. 1. Biochemical pathways and chemical structures of organosulfur compounds. 
(Alk(en)yl cysteine sulfoxides (ACOs); Propyl-propane-thiosulfonate (PTSO); Propyl-
propane-thiosulfinate (PTS)). 
 
Fig. 2. Mean body weights (g) of A) male and B) female rats orally exposed to 0, 
14, 28 and 55 mg/kg b.w./day PTSO and control rats for 90 days. 
 
Fig. 3. Mean body weight gain (%) of A) male and B) female rats orally exposed to 
0, 14, 28 and 55 mg/kg b.w./day PTSO and control rats for 90 days. 
 
Fig. 4. Histopathological study of liver, kidney, spleen, heart, brain, pituitary, 
stomach, intestines, lung, testes, and and skeletal muscle of untreated Sprague Dawley 
rats, control (A), and treated (B) with PTSO (55 mg/Kg/day) for 90 days (bars= 50 µm). 
In the liver, normal hepatic cords and normal polyhedral hepatocytes with central 
nucleus and clear cytoplasm are seen in control and exposed animals. In the kidney, the 
renal parenchyma with normal glomeruli and renal tubules is shown in control rats (A), 
as well as in rats treated with the highest dose of PTSO (B). Detail of the apparently 
normal spleen parenchyma in control and treated rats (A, B). In the heart, normal 
cardiac fibers were observed in all groups (A, B). In the brain, the motions of the 
cerebral cortex are normal (A, B). Details of the apparently normal pituitary are 
observed in control and treated rats (A, B). Detail of the stomach with apparently 
normal mucous and glandular cells in control and treated rats (A, B). Intestinal villi with 
abundant apparently normal enterocytes are shown in all groups. Detail of the control 
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bronchial epithelium, without alterations in the bronchi and alveoli in the untreated rats 
(A) as well as in the rats treated with the highest dose (B). Male rat testes showed 
normal seminiferous tubules and interstitial space (A) that is maintained in treated male 
rats (B). The ovaries of the treated and control female rats (A, B) presented normal 
follicles in all groups. Detail of the normal striated skeletal muscle of the treated and 
























Table 1. Effect of 90 days oral exposure to PTSO on body weight and food 
consumption in rats. Values represent the mean ±SD of 10 rats/sex/group. Differences 
between control and treated groups for male and female rats were evaluated by Kruskal-
Wallis test (K.W.) or by ANOVA test (F values). 
 
Table 2. Hematology parameters of male and female rats fed with 0, 14, 28 and 55 
mg/kg b.w./day PTSO for 90-days. Values are mean ± SD for 10 rats/sex/group. The 
differences between control and treated groups for male and female rats were evaluated 
by Kruskal-Wallis test (K.W.) or by ANOVA test (F values). The significance levels 
observed are & in comparison to group 4 (55 mg/Kg/d) when p<0.05, and # in 
comparison to group 3 (28 mg/Kg/d) when p<0.05. 
 
Table 3. Differential White blood cells count data of male and female rats fed with 
0, 14, 28 and 55 mg/kg b.w./day PTSO for 90-days. Values are mean ± SD for 10 
rats/sex/group. The differences between control and treated groups for male and female 
rats were evaluated by Kruskal-Wallis test (K.W.) or by ANOVA test (F values). 
 
Table 4. Clinical biochemistry of male and female rats fed with 0, 14, 28 and 55 
mg/kg b.w./d PTSO for 90-days. Values are mean ± SD for 10 rats/sex/group. The 
differences between control and treated groups for male and female rats were evaluated 
by Kruskal-Wallis test (K.W.) or by ANOVA test (F values). The significance levels 




Table 5. Absolute organ weight of male and female rats fed with 0, 14, 28 and 55 
mg/kg b.w./day PTSO for 90-days. Values are mean ± SD for 10 rats/sex/group. The 
differences between control and treated groups for male and female rats were evaluated 
by Kruskal-Wallis test (K.W.) or by ANOVA test (F values). The significance levels 
observed are *p < 0.05 in comparison to control group values. 
 
Table 6. Relative organ weight/body weight of male and female rats fed with 0, 14, 
28 and 55 mg/kg b.w./day PTSO for 90-days. Values are mean ± SD for 10 
rats/sex/group. The differences between control and treated groups for male and female 
rats were evaluated by Kruskal-Wallis test (K.W.) or by ANOVA test (F values). 
 
Table 7. Relative organ weight/brain weight of male and female rats fed with 0, 14, 
28 and 55 mg/kg b.w./day PTSO for 90-days. Values are mean ± SD for 10 
rats/sex/group. The differences between control and treated groups for male and female 















Values are mean ± SD for 10 rats/sex/group. F: Statistics ANOVA test;  K.W: Kruskal-Wallis Statistic; N.S.: Not Significant. 
 
 
  MALE FEMALE 
PARAMETERS 
Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4 
(0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) (0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) 
N=10 N=10 N=10 N=10 N=10 N=10 N=10 N=10 
Inicial body 
weight (g) 
320.1±10.8 317.4±8.7 321.4±14.0 320.3±14.7 226.5±9.2 228.6±14.6 227.3±10.1 225.3±12.3 
F(36.3)=0.19 p=0.90; N.S. F(36.3)= 0.14 p=0.94; N.S. 
Final body weight 
(g) 
633.8±38.3 623.1±28.7 611.5±26.5 625.9±48.1 326.8±11.5 338.0±29.1 321.1±23.8 321.3±18.3 
F(36.3)=0.64 p=0.59; N.S. F(36.3)=1.33 p=0.28; N.S. 
Body weight gain 
313.7 ±35.4 305.7±29.5 290.1±29.2 305.6±38.2 100.3± 13.5 109.4±19.9 93.8±23.3 96.0±15.5 
F(36.3)=0.88 p=0.46; N.S F(36.3)=1.40 p=0.26; N.S. 
Total feed intake 
(g) 
2977.2±197.2 2998.0±207.0 2822.1±249.2 2810.5±155.5 1948.4±174.2 1994.9±258.8 1928.3±210.7 1888.3±142.6 




9.6±0.8 9.9±1.4 9.8±1.0 9.3±0.9 19.8±3.2 18.5±2.5 21.3±3.7 20.3±4.6 




















HAEMATOLOGY DATA SUMMARY  
    MALE FEMALE 
    Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4 
    (0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) (0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) 
    N=10 N=10 N=10 N=10 N=10 N=10 N=10 N=10 
RBC MEAN 9.08 9.08 9.13 8.78 8.40 8.81 8.48 7.75 
106/µl ST. DEV. 0.53 0.35 0.59 0.64 0.29 0.53 0.20 1.43 
  F(36.3)=0.82 p=0.49; N.S. KW=6.57 p=0.09; N.S. 
HGB MEAN 14.79 15.02 15.08 14.72 14.30 14.76 14.88 13.26 
g/dL ST. DEV. 1.11 0.64 0.91 0.76 0.62 0.59 0.49 2.41 
  F(36.3)=0.35 p=0.79; N.S. KW= 7.03 p=0.07; N.S. 
HCT MEAN 70.10 70.20 70.63 68.89 70.00 72.89
& 72.70& 64.10 
% ST. DEV. 3.48 2.78 3.74 3.10 3.35 3.76 2.91 11.88 
  F(36.3)=0.46 p=0.72; N.S. KW= 8.77 
& p<0.03. 
MCV MEAN 77.29 77.42 77.46 78.57 83.23 82.80 85.95 82.50 
fL ST. DEV. 2.54 2.12 3.50 3.34 2.52 2.66 3.14 2.27 
  F(36.3)=0.39 p=0.76; N.S. KW=7.67 p=0.05; N.S. 
MCH MEAN 16.29 16.55 16.55 16.81 17.02 16.78
# 17.53 17.12 
pg ST. DEV. 1.26 0.40 0.74 0.66 0.52 0.76 0.55 0.26 
  F(36.3)=0.62 p=0.61; N.S. F(34.3)=3.12 
#p<0.04. 
MCHC MEAN 21.07 21.39 21.35 21.36 20.47 20.26 20.40 20.68 
g/dL ST. DEV. 1.22 0.38 0.38 0.35 0.30 0.44 0.40 0.33 
  F(36.3)=0.43 p =0.73; N.S. F(34.3)=2.12 p=0.12 ; N.S. 
PLT MEAN 891.50 912.50 1001.00 899.00 666.67 780.67 810.50 726.00 
103/µl ST. DEV. 247.31 219.09 221.36 241.41 345.75 283.76 252.44 407.29 
  F(36.3)=0.40 p=0.76; N.S. F(34.3)=0.29 p=0.83; N.S. 
RDW MEAN 16.67 17.26 16.90 15.98 14.02 14.62 14.46 15.02 
% ST. DEV. 1.11 1.03 1.53 1.52 0.34 1.11 0.89 1.50 
  F(36.3)=1.61 p=0.21; N.S. KW= 2.49  p=0.48; N.S. 
T PRO MEAN 22.33 22.49 21.27 24.79 21.68 22.55 21.78 22.10 
seg ST. DEV. 4.92 3.77 0.62 4.22 1.41 1.03 1.19 0.49 
  KW=4.19 p=0.24; N.S. F(34.3)=1.01 p=0.40; N.S. 
T CEF MEAN 34.30 35.38 34.12 27.65 36.03 33.45 33.80 33.63 
seg ST. DEV. 6.52 8.00 7.61 6.94 3.86 2.85 4.01 3.55 
  KW=4.97 p=0.17; N.S. F(34.3)=0.96 p=0.46; N.S. 
Table 2
RBC: Erythrocyte count; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; PLT: 
platelet (thrombocyte) count; RDW: red blood cell distribution width; T PRO: prothrombin time; T CEF: cephalin time. F: Statistics ANOVA test; K.W: Kruskal-WallisStatistic; N.S.: Not Significant; 


















WBC: total leukocyte count; NE: neutrophil; LY: lymphocyte; MO: monocyte; EO: eosinophil; BA: basophil; F: Statistics ANOVA test; K.W: Kruskal-Wallis Statistic; N.S.: Not Significant. 
 
DIFFERENTIAL WHITE BLOOD CELLS COUNT DATA SUMMARY  
    MALE FEMALE 
    Group 1 Group 2  Group 3  Group 4  Group 1 Group 2  Group 3  Group 4  
    (0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) (0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) 
    N=10 N=10 N=10 N=10 N=10 N=10 N=10 N=10 
WBC MEAN 11.43 11.84 12.03 11.70 7.19 6.02 6.83 4.54 
103/µL ST. DEV. 3.38 1.70 1.88 3.80 3.67 1.93 2.16 2.70 
  KW= 0.60 p=0.90; N.S. F(34.3)=1.86 p=0.16; N.S. 
NE MEAN 16.43 14.59 16.07 16.95 30.24 31.03 24.66 24.99 
% ST. DEV. 5.07 2.80 3.53 5.88 27.30 15.46 15.28 11.31 
  KW=1.47 p=0.69; N.S. F(34.3)=0.35 p=0.79; N.S. 
LY MEAN 71.87 80.02 78.09 74.52 64.73 62.00 68.32 67.00 
% ST. DEV. 14.48 4.25 5.78 8.01 26.04 17.24 14.42 12.00 
  KW= 5.07 p=0.17; N.S. F(34.3)=0.25 p=0.86; N.S. 
MO MEAN 3.01 1.52 2.87 2.94 1.44 1.07 0.75 1.57 
% ST. DEV. 2.24 1.81 2.33 2.16 1.66 0.74 0.77 1.78 
  KW=2.71 p=0.44; N.S. KW=2.22 p=0.53; N.S. 
EO MEAN 3.38 3.22 2.03 4.58 3.17 6.33 4.52 6.94 
% ST. DEV. 2.33 1.69 0.58 2.88 2.52 4.53 2.90 5.23 
  KW=6.70 p=0.08; N.S. KW=3.14 p=0.37; N.S. 
BA MEAN 0.57 0.70 0.95 1.07 0.41 0.54 0.80 0.51 
% ST. DEV. 0.50 0.44 1.39 1.09 0.41 0.41 0.65 0.39 
  KW=1.42p=0.70; N.S. F(34.3)= 1.01 p=0.40; N.S. 
Table 3
Table 4 
CLINICAL BIOCHEMISTRY DATA SUMMARY  
    MALE FEMALE 
    Group 1 Group 2  Group 3  Group 4  Group 1 Group 2  Group 3  Group 4  
    (0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) (0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) 
    N=10 N=10 N=10 N=10 N=10 N=10 N=10 N=10 
GLUC MEAN 143.50 146.50 128.40 123.60 125.60 121.60 105.20 104.00 
mg/dL ST. DEV. 22.73 27.44 26.31 20.30 16.64 17.20 27.59 44.93 
    F(36.3)=2.12 p=0.12; N.S. KW=4.90 p=0.18; N.S. 
UREA MEAN 35.22 31.67 33.99 35.37 30.26 31.87 34.90 34.22 
mg/dl ST. DEV. 4.83 2.95 4.37 3.16 4.63 3.36 7.02 4.14 
  F(36.3)=1.92 p=0.14; N.S. F(36.3)=1.85 p=0.16; N.S. 
CREAT MEAN 0.30 0.28 0.29 0.29 0.34 0.35 0.35 0.34 
mg/dL ST. DEV. 0.04 0.02 0.03 0.03 0.06 0.03 0.07 0.02 
    F(36.3)=0.48 p=0.70; N.S. F(36.3)=0.26 p=0.86; N.S. 
BILI-T MEAN 0.21 0.31 0.21 0.22 0.26 0.28 0.25 0.26 
mg/dL ST. DEV. 0.02 0.32 0.02 0.03 0.03 0.02 0.03 0.01 
    KW=1.41 p=0.70; N.S. F(36.3)=2.15 p=0.11; N.S. 
CHOL MEAN 107.50 95.40 93.50 88.50** 104.20 101.80 112.40 99.20 
mg/dL ST. DEV. 13.83 15.36 10.60 8.50 11.12 20.75 20.58 15.36 
    F(36.3)=4.25 p<0.01** F(36.3)=1.08 p=0.36; N.S. 
TRIGL MEAN 156.40 163.40* 131.80 123.00 78.60 104.80 84.40 77.80 
mg/dL ST. DEV. 33.81 36.16 27.59 20.96 18.87 28.06 21.53 16.94 
    KW=10.48 p<0.05* F(36.3)=1.85 p=0.16; N.S. 
AST MEAN 147.52 145.76 135.39 183.73 264.52 246.91 251.94 264.62 
U/L ST. DEV. 17.74 26.66 17.66 101.03 94.90 92.11 73.01 122.10 
    KW=3.44 p=0.33; N.S. KW= 0.39 p=0.95; N.S. 
ALT MEAN 30.46 38.36 33.42 31.44 38.31 35.40 37.03 35.22 
U/L ST. DEV. 6.26 16.86 6.09 2.42 10.34 17.81 5.26 10.55 
    KW=3.12 p=0.38; N.S. KW=2.41 p=0.49; N.S. 
ALKP MEAN 91.20 98.20 88.30 89.60 62.00 62.90 66.40 60.60 












GLUC: glucose; CREAT: creatinine; Bili-T: Bilirubin, total; CHOL:cholesterol, total; TRIGL: triglycerides; AST:aspartate aminotransferase; ALT: alanine aminotransferase; ALKP: alkaline phosphatase; ALB:albumin;  TOT PROT: protein, total; 
Na+:sodium; K+:potassium; Ca++: calcium. 
F: Statistics ANOVA test; K.W:Kruskal-WallisStatistic; N.S.: Not Significant 
*Significantly different from control. *when p<0.01 
**Significantly different from control. **when p<0.01 
 
    KW=0.56 p=0.65; N.S. F(36.3)=0.39 p=0.76; N.S. 
ALB MEAN 3.93 3.88 3.98 4.00 4.80 4.59 4.66 4.72 
g/dl ST. DEV. 0.47 0.25 0.32 0.29 0.35 0.34 0.59 0.34 
    KW=1.54 p=0.67; N.S. F(36.3)=0.47 p=0.70; N.S. 
TOT PROT MEAN 6.24 6.26 6.26 6.20 6.46 6.78 6.78 6.54 
g/dl ST. DEV. 0.34 0.48 0.37 0.29 0.44 0.35 0.68 0.51 
    F(36.3)=0.06 p=0.98; N.S. F(36.3)=1.05 p=0.38; N.S. 
Na+ MEAN 134.80 133.70 133.60 132.80 142.60 139.60 140.20 139.40 
mmol/L ST. DEV. 10.40 3.59 3.24 4.08 4.62 7.12 11.64 7.78 
    KW=2.00 p=0.57; N.S. KW=1.65 p=0.65; N.S. 
K+ MEAN 7.87 8.89 7.90 8.38 9.68 12.81 14.93 10.34 
mmol/L ST. DEV. 1.58 1.62 0.77 1.29 6.97 6.18 7.61 5.67 
    F(36.3)=1.26 p=0.30; N.S. KW=6.35 p=0.10; N.S. 
Ca++ MEAN 10.87 10.28 10.82 10.51 11.30 11.42 10.76 11.25 
mg/dL ST. DEV. 1.04 0.66 0.64 0.47 1.06 1.26 0.87 1.36 
  KW=4.43 p=0.22; N.S. KW=2.34 p=0.51; N.S. 
Table 5 
 
F: Statistics ANOVA test; K.W: Kruskal-Wallis Statistic; N.S.: Not Significant. * Significantly different from group 3 in comparison to group 1 when p<0.05. 
ORGAN WEIGHT DATA SUMMARY 
MALE FEMALE 
    Group 1 Group 2  Group 3  Group 4        Group 1 Group 2  Group 3  Group 4  
  
 
(0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day)   
  
(0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) 
   N=10 N=10 N=10 N=10    N=10 N=10 N=10 N=10 
BODY W. MEAN 633.80 623.10 611.5 625.90 BODY W. MEAN 326.80 338.00 321.10 321.30 
(g) ST. DEV. 38.25 28.71 26.50 48.14 (g) ST. DEV. 11.50 29.08 23.81 18.31 
F(36.3)=0.19 p=0.90; N.S. F(36.3)=1.34 p=0.29; N.S. 
BRAIN MEAN 2.09 2.13 2.12 2.07 BRAIN MEAN 1.96 2.03 2.01 2.06 
(g) ST. DEV. 0.21 0.14 0.17 0.23 (g) ST. DEV. 0.21 0.10 0.12 0.15 
KW=0.09 p=0.99; N.S. KW=2.35 p=0.50; N.S. 
LIVER MEAN 21.06 18.49 18.40 18.41 LIVER MEAN 8.41 9.54 8.90 8.48 
(g) ST. DEV. 4.86 1.45 1.77 2.40 (g) ST. DEV. 1.36 1.09 1.08 0.83 
F(36.3)=1.99 p=0.13; N.S. F(36.3)=2.21 p=0.10; N.S. 
HEART MEAN 2.14 1.98 1.82* 1.99 HEART MEAN 1.21 1.28 1.20 1.22 
(g) ST. DEV. 0.18 0.19 0.19 0.32 (g) ST. DEV. 0.13 0.13 0.14 0.16 
   F(36.3)=3.11 *p<0.05    F(36.3)=0.67 p=0.59; N.S. 
SPLEEN MEAN 1.17 1.16 1.16 1.45 SPLEEN MEAN 0.80 0.86 0.74 0.75 
(g) ST. DEV. 0.10 0.15 0.14 0.93 (g) ST. DEV. 0.11 0.19 0.07 0.09 
KW=0.2426 p=0.9704; N.S. F(36.3)=1.71 p=0.18; N.S. 
KIDNEYS MEAN 4.05 4.10 3.99 4.06 KIDNEYS MEAN 2.13 2.30 2.15 2.06 
(g) ST. DEV. 0.30 0.41 0.37 0.28 (g) ST. DEV. 0.23 0.23 0.20 0.14 
   F(36.3)=0.17 p=0.92; N.S. F(36.3)=2.48  p=0.08; N.S. 
THYMUS MEAN 0.88 0.80 0.83 0.71 THYMUS MEAN 0.67 0.70 0.66 0.60 
(g) ST. DEV. 0.25 0.12 0.15 0.27 (g) ST. DEV. 0.08 0.13 0.20 0.10 
    F(36.3)=1.20 p=0.32; N.S. F(36.3)=1.02 p=0.40; N.S. 
TESTES MEAN 3.92 3.95 3.77 3.83 UTE./CERV. MEAN 0.87 0.76 1.03 0.94 
(g) ST. DEV. 0.44 0.29 0.32 0.28 (g) ST. DEV. 0.24 0.17 0.81 0.32 
      F(36.3)=0.62 p=0.61; N.S. KW=1.32 p=0.73; N.S. 
EPIDIDIMS MEAN 1.88 2.05 2.36 2.07 OVARIES MEAN 0.26 0.31 0.23 0.25 
(g) ST. DEV. 0.24 0.52 0.98 0.28 (g) ST. DEV. 0.0.8 0.10 0.06 0.07 
    KW=4.00 p=0.26; N.S. F(36.3)= 1.90 p=0.15; N.S. 
ADRENALS MEAN 0.11 0.13 0.12 0.12 ADRENALS MEAN 0.15 0.12 0.10 0.12 
(g) ST. DEV. 0.04 0.05 0.07 0.05 (g) ST. DEV. 0.08 0.04 0.02 0.08 





F: Statistics ANOVA test; K.W: Kruskal-Wallis Statistic; N.S.: Not Significant. 
 
ORGAN WEIGHT/BODY WEIGHT RATIO DATA SUMMARY 
MALE FEMALE 
    Group 1 Group 2  Group 3  Group 4        Group 1 Group 2  Group 3  Group 4  
  
 
(0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day)   
  
(0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) 
   N=10 N=10 N=10 N=10    N=10 N=10 N=10 N=10 
BRAIN MEAN 0.33 0.34 0.36 0.33 BRAIN MEAN 0.60 0.60 0.63 0.64 
(%) ST. DEV. 0.03 0.03 0.06 0.04 (%) ST. DEV. 0.07 0.05 0.6 0.05 
KW=4.99 p=0.17; N.S. F(36.3)=1.17 p=0.34; N.S. 
LIVER MEAN 3.31 2.97 3.22 2.93 LIVER MEAN 2.58 2.82 0.77 2.64 
(%) ST. DEV. 0.71 0.15 0.71 0.21 (%) ST. DEV. 0.42 0.23 0.27 0.24 
KW=2.03 p=0.57; N.S. F(36.3)=1.47 p=0.24; N.S. 
HEART MEAN 0.33 0.31 0.32 0.32 HEART MEAN 0.37 0.38 0.38 0.38 
(%) ST. DEV. 0.04 0.02 0.05 0.05 (%) ST. DEV. 0.04 0.05 0.06 0.05 
   F(36.3)=0.64 p=0.59; N.S.    KW=1.12 p=0.77; N.S. 
SPLEEN MEAN 0.18 0.19 0.20 0.23 SPLEEN MEAN 0.25 0.25 0.23 0.23 
(%) ST. DEV. 0.02 0.02 0.03 0.14 (%) ST. DEV. 0.03 0.05 0.02 0.03 
KW=2.15 p=0.54; N.S. F(36.3)=0.76 p=0.52; N.S. 
KIDNEYS MEAN 0.63 0.65 0.70 0.65 KIDNEYS MEAN 0.65 0.68 0.67 0.64 
(%) ST. DEV. 0.05 0.05 0.15 0.06 (%) ST. DEV. 0.07 0.06 0.06 0.06 
KW=1.42 p=0.70; N.S. KW=2.53 p=0.47; N.S. 
THYMUS MEAN 0.14 0.13 0.15 0.11 THYMUS MEAN 0.21 0.21 0.21 0.19 
(%) ST. DEV. 0.02 0.02 0.05 0.04 (%) ST. DEV. 0.03 0.04 0.06 0.03 
    KW=4.80 p=0.19; N.S. F(36.3)=0.68 p=0.57; N.S. 
TESTES MEAN 0.62 0.63 0.66 0.61 UTE./CERV. MEAN 0.27 0.23 0.32 0.29 
(%) ST. DEV. 0.07 0.05 0.14 0.07 (%) ST. DEV. 0.07 0.05 0.25 0.10 
      KW=1.16 p=0.76; N.S. KW=2.47 p=0.48; N.S. 
EPIDIDIMS MEAN 0.30 0.32 0.41 0.33 OVARIES MEAN 0.08 0.09 0.07 0.08 
(%) ST. DEV. 0.04 0.08 0.18 0.05 (%) ST. DEV. 0.02 0.03 0.02 0.02 
KW=5.544 p=0.1361; N.S. KW=3.53 p=0.32; N.S. 
ADRENALS MEAN 0.02 0.02 0.02 0.02 ADRENALS MEAN 0.05 0.04 0.03 0.04 
(%) ST. DEV. 0.01 0.01 0.01 0.01 (%) ST. DEV. 0.02 0.01 0.01 0.02 




F: Statistics ANOVA test; K.W: Kruskal-Wallis Statistic; N.S.: Not Significant. 
 
ORGAN WEIGHT/BRAIN WEIGHT RATIO DATA SUMMARY 
MALE  FEMALE 
    Group 1 Group 2  Group 3  Group 4        Group 1 Group 2  Group 3  Group 4  
  
 
(0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day)   
  
(0 mg/Kg/day) (14 mg/Kg/day) (28 mg/Kg/day) (55 mg/Kg/day) 
   N=10 N=10 N=10 N=10    N=10 N=10 N=10 N=10 
LIVER MEAN 1011.66 874.10 876.04 892.82 LIVER MEAN 437.12 470.10 444.59 411.74 
(%) ST. DEV. 229.58 103.29 131.13 92.16 (%) ST. DEV. 104.65 48.18 56.83 41.47 
KW=4.08 p=0.25; N.S. F(36.3)=1.27 p=0.30; N.S. 
HEART MEAN 103.79 93.72 86.79 97.94 HEART MEAN 62.93 63.41 60.00 59.58 
(%) ST. DEV. 16.99 12.97 10.89 23.79 (%) ST. DEV. 13.12 8.56 8.83 9.81 
   KW=6.19 p=0.10; N.S.    F(36.3)=0.37 p=0.78; N.S. 
SPLEEN MEAN 56.36 54.78 55.10 55.42 SPLEEN MEAN 41.83 42.21 37.10 36.61 
(%) ST. DEV. 7.85 6.83    7.14 7.75 (%) ST. DEV. 9.96 9.33 3.40 6.17 
   F(36.3)=0.084 p=0.97; N.S. F(36.3)=1.52 p=0.23; N.S. 
KIDNEYS MEAN 195.30 193.90 190.21 198.22 KIDNEYS MEAN 110.18 113.37 107.39 100.25 
(%) ST. DEV. 22.29 27.64 30.06 26.91 (%) ST. DEV. 18.71 12.13 13.40 12.68 
F(36.3)=0.15 p=0.93; N.S. KW=5.94 p=0.11; N.S. 
THYMUS MEAN 42.63 37.87 39.25 34.33 THYMUS MEAN 34.57 34.51 33.29 28.27 
(%) ST. DEV. 13.08 6.61 7.85 12.04 (%) ST. DEV. 5.25 5.96 12.14 4.26 
    F(36.3)=1.13 p=0.35; N.S. KW=5.75 p=0.12; N.S. 
TESTES MEAN 189.99 187.00 179.45 187.33 UTE./CERV. MEAN 44.81 37.40 51.51 46.40 
(%) ST. DEV. 33.59 23.50 24.34 28.69 (%) ST. DEV. 12.42 8.40 40.13 18.00 
    F(36.3)=0.26 p=0.85; N.S. KW=2.62 p=0.45; N.S. 
EPIDIDIMS MEAN 89.92 96.89 112.09 100.46 OVARIES MEAN 13.04 15.32 11.31 12.10 
(%) ST. DEV. 7.49 24.61 46.97 12.46 (%) ST. DEV. 3.734 5.41 3.20 3.43 
    KW=3.96 p=0.27; N.S.       F(36.3)=1.85 p=0.16; N.S. 
ADRENALS MEAN 5.42 5.40 5.91 5.75 ADRENALS MEAN 8.00 6.10 4.82 5.98 
(%) ST. DEV. 2.59 2.83 3.99 2.77 (%) ST. DEV. 4.87 2.02 1.33 3.97 
KW=0.50 p=0.92; N.S. KW=4.27 p=0.23; N.S. 
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